Abstract
Background
The diffuse sclerosing (DSV) and tall cell (TCV) variants are considered aggressive subtypes of papillary thyroid cancer (PTC) for which data are limited.
Methods
The Surveillance, Epidemiology, and End Results (SEER) database (1988–2008) was used to compare the incidence and clinical/pathologic characteristics of DSV and TCV with classic PTC. Prognostic factors associated with survival were analyzed by chi-square test, analysis of variance, log rank test, and Cox multivariate regression.
Results
There were 261 DSV, 573 TCV, and 42,904 PTC patients. Compared to a 60.8% increase in classic PTC incidence, DSV and TCV incidence increased by 126% (P trend = 0.052) and 158% (P trend = 0.002), respectively. Aggressive variants were associated with higher rates of extrathyroidal extension, multifocality, and nodal and distant metastasis (all P < 0.001) compared to classic PTC. Nodal metastasis was more likely with DSV (72.2% vs. 66.8% TCV vs. 56.3% PTC, P < 0.001); distant metastasis was most common with TCV (11.1% vs. 7.3% DSV vs. 4.3% PTC, P < 0.001). After adjustment, DSV [hazard ratio (HR) 1.8, P = 0.007] and TCV (HR 1.9, P < 0.001) histologies were associated with significantly reduced survival (5-year overall: 87.5% DSV, 80.6% TCV vs. 93.5% PTC, P < 0.001). Tumor size independently predicted worse prognosis for TCV (HR 1.29, P < 0.001) but not DSV patients. Thyroid surgery and radioiodine improved survival of DSV and TCV patients (all P < 0.05). Patients with aggressive variants who received external-beam radiotherapy did not experience improved survival.
Conclusions
DSV and TCV are rare, increasing in incidence, and have a worse prognosis than classic PTC. Patients with these variants should be treated aggressively with thyroidectomy and radioiodine, regardless of tumor size.
Similar content being viewed by others
References
Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–14.
Clark OH. Thyroid cancer and lymph node metastases. J Surg Oncol. 2011;103:615–8.
Carling T, Ocal I, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31:916–23.
Khanafshar E, Lloyd RV. The spectrum of papillary thyroid carcinoma variants. Adv Anat Pathol. 2011;18:90–7.
Patel KN, Shaha AR. Poorly differentiated and anaplstic thyroid cancer. Cancer Control. 2006;13:119–28.
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive variants of papillary thyroid carcinoma. Head Neck. 2010;33:1052–9.
Regalbuto C, Malandrino P, Tumminia A, Le Moli R, Vigneri R, Pezzino V. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid. 2011;21:383–9.
Lam A, Lo C, Lam K. Papillary carcinoma of thyroid: a 30-year clinicopathological review of the histological variants. Endocr Pathol. 2005;16:323–30.
Morris LGT, Myssiorek D. Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. Am J Surg. 2010;200:454–61.
Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol. 2004;86:44–54.
Ghossein R, Livolsi VA. Papillary thyroid carcinoma tall cell variant. Thyroid. 2008;18:1179–81.
Michels JJ, Jacques M, Henry-Amar M, Bardet S. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007;38:212–9.
Terry JH, John SAS, Karkowski FJ, et al. Tall cell papillary thyroid cancer: incidence and prognosis. Am J Surg. 1994;168:459–61.
Fujimoto Y, Obara T, Ito Y, Kodama T, Aiba M, Yamaguchi K. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Clinical importance, surgical treatment and follow-up study. Cancer. 1990;66:2306–12.
Carangiu ML. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol. 1989;13:1041–9.
Wu PS, Leslie PJ, McLaren KM, Toft AD. Diffuse sclerosing papillary carcinoma of thyroid: a wolf in sheep’s clothing. Clin Endocrinol (Oxf). 1989;31:535–40.
McElvanna K, McCusker G, Stirling I. Diffuse sclerosing variant of papillary thyroid carcinoma—a rare cause of goitre in a young patient. Ulster Med J .2007;76:113–4.
Falvo L, Giacomelli L, D’Andrea V, Marzullo A, Guerriero G, De Antoni E. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg. 2006;72:438–44.
Morris LGT, Shaha AR, Tuttle RM, Sikora AG, Ganly I. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20:153–8.
Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17:655–61.
Chow SM, Chan JK, Law SC, et al. Diffuse sclerosing variant of papillary thyroid carcinoma—clinical features and outcome. Eur J Surg Oncol. 2003;29:446–9.
National Cancer Institute. Overview of the surveillance epidemiology and end results program. http://seer.about.gov/about. Accessed 4 Nov 2011.
Akslen LA, Varhaug JE. Thyroid carcinoma with mixed tall-cell and columnar-cell features. Am J Clin Pathol. 1990;94:442–5.
Pilotti S, Collini P, Manzari A. Poorly differentiated forms of papillary thyroid carcinoma: distinctive entities or morphological patterns? Semin Diagn Pathol. 1995;82:740–53.
Wenig BM, Thompson LDR, Adair CF, Shmookler B, Heffess CS. Thyroid papillary carcinoma of columnar cell type. Cancer. 1998;82:740–53.
National Cancer Institute. Staging information for thyroid cancer. http://www.cancer.gov/cancertopics/pdq/treatment/thyroid/HealthProfessional/page3. Accessed 4 Nov 2011.
Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results national cancer data registry. Surgery. 2010;148:1147–53.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.
Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–91.
Hodgson N, Button J, Solorzano C. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11:1093–7.
Hughes DT, Haymart MR, Miller BS, Gauger PG, Doherty GM. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid. 2011;21:231–6.
Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope. 2008;118:32–8.
Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88:1902–8.
Sheu SY, Schwertheim S, Worm K, Grabellus F, Schmid KW. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol. 2007;20:779–87.
Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies muc1 as an independent prognostic marker. Cancer Res. 2004;64:3780–9.
Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30:216–22.
Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W. Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol. 1992;23:1395–401.
Koo JS, Hong S, Park CS. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid. 2009;19:1225–31.
Thompson L, Wieneke J, Heffess C. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol. 2005;16:331–48.
Brown RL. Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol. 2008;35:298–308.
Elaraj DM, Sturgeon C. Adequate surgery for papillary thyroid cancer. Surgeon. 2009;7:286–9.
Disclosure
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kazaure, H.S., Roman, S.A. & Sosa, J.A. Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients. Ann Surg Oncol 19, 1874–1880 (2012). https://doi.org/10.1245/s10434-011-2129-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-011-2129-x